Background: Intraventricular hemorrhage is a significant cause of mortality and morbidity worldwide. Treating intraventricular hemorrhage with intraventricular fibrinolytic therapy via a catheter is becoming an increasingly utilized intervention.
Introduction
Intracerebral hemorrhage (ICH) is a significant cause of mortality and morbidity worldwide. These hemorrhages often have ventricular involvement, defined as secondary intraventricular hemorrhage (IVH). Primary IVH occurs within the ventricles without parenchymal involvement and is rare, comprising 3.1% to 9% of ICH cases. 1, 2 Primary IVH has been correlated with better prognosis indicating that further research is needed to assess differences between these diseases. 3 IVH can occur from various etiologies such as hypertension, Moyamoya disease, arteriovenous malformations (AVMs), clotting disorders, and cerebral aneurysms. 1 Furthermore, concurrent pathophysiological processes such as high mean arterial pressure, high baseline ICH volume, antithrombotic use, diabetes, and small vessel disease can increase risk for IVH. 4, 5 IVH increases the rates of mortality and morbidity through complications such as elevated intracranial pressure (ICP), obstructive hydrocephalus, and exposure to toxic blood degradation products. [6] [7] [8] IVH is an independent predictor of mortality. 9 When treated, the most common intervention for ICH with IVH is insertion of an extraventricular drain (EVD), which allows drainage of blood products and cerebrospinal fluid to control ICP. However, an EVD can become obstructed and require replacement, which places patients at risk for high ICP and limits removal of IVH. 10 Treating IVH with intraventricular fibrinolytic (IVF) therapy such as alteplase via an EVD compared to EVD alone shows trends for increased use. 11, 12 Fibrinolytics accelerate the degradation and removal of the clot and shorten the brain's exposure to toxic blood products. These properties account for current therapeutic interest. 7, 8, 13 Recent literature demonstrates that IVF therapy is safe for treatment of IVH. 14 Additionally, two previous meta-analyses have reported improved mortality of EVD with IVF compared to EVD alone and varying degrees of improvement in functional outcome depending on study design. 7, 10 Following completion of Clot Lysis Evaluation of Accelerated Resolution of Intraventricular Hemorrhage (CLEAR III), a 500 patient randomized controlled trial comparing EVD with IVF and EVD with saline, a larger patient cohort is available to update past meta-analyses with quality longitudinal data related to functional outcomes. 7 This meta-analysis omitted patients with AVMs, brain tumors, vascular abnormalities, and trauma cases as causes of IVH to focus on a more homogenous IVH population to demonstrate outcome trends for patients with spontaneous hypertensive IVH. Mortality and good functional outcome (GFO) after IVF therapy was reviewed across all publications meeting the inclusion criteria.
Search strategy and selection criteria
PubMed and China databases CNKI, VIP, and Wanfang were searched using the terms ''IVH'' and ''IVH and ICH'' for studies published between January 1950 and July 2016. Data were independently extracted by two authors (AB and KR) following PRISMA guidelines. The following inclusion criteria were followed for publications: adult (older than 18 years old) patients, supratentorial ICH, IVH, hypertensive etiology, an EVD alone or EVD plus saline control group, outcomes listed (i.e., mortality, modified Rankin Scale [mRS], or Glasgow Outcome Scale [GOS]), and studies where the treatment of IVH with IVF was the primary intervention studied. Finally, only patients without vascular abnormalities were included (e.g., aneurysms and AVM). For three publications with individual patient data, subjects with vascular abnormalities were selectively removed from analysis.
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Methods
Mortality and functional outcome data, mRS and GOS, were collected at 30, 90, 180, and 365 day time points, when available, for all 17 studies. GFO was defined as a mRS score of 0 to 3 and a GOS score of 3 to 5, which is common neurocritical care designation. The scale designated as the primary end point (i.e., mRS or GOS) for these publications, was used for the combined GFO analysis. Publication quality was assessed using the Jadad scale for randomized trials; the Newcastle-Ottawa Scale (NOS) was used for nonrandomized studies.
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Statistical analysis
All statistical analyses were performed using Stata 14.0 (Stata, College Station, Texas). Mantel-Haenszel fixedeffects and DerSimonian and Laird random-effects models were used to calculate the combined effect sizes, confidence intervals (CIs) for the combined relative risk estimates, and P values for a hypothesis regarding the combined estimate per timepoint. 20 P values less than 0.05 were considered significant. Results were displayed graphically as forest plots. Individual studies were weighted within their respective time point per outcome measure.
A funnel plot was used to plot the precision (1/standard error) against the treatment effect to assess publication bias (Supplemental Figure A) . 21, 22 Degree of heterogeneity was identified according to the Cochrane Handbook for Systematic Reviews of Interventions guidelines. An I 2 value less than 30% was considered low heterogeneity, an I 2 between 30% and 50% moderate, an I 2 between 50% and 75% substantial, and an I 2 greater than 75% was classified as considerable. 23 Sensitivity analyses were performed to show how each trial influenced the various outcome measures. The sensitivity analyses were done at each time point for mortality, combined GFO, GOS, and mRS by removing one study at a time and reviewing its effect on the overall estimate. For the sensitivity analyses, International Journal of Stroke, 13 (1) a ''fixed-effects model'' was used if heterogeneity was less than 50% and a ''random-effects mode'' if it was greater than 50%. Additionally, Egger regressions were conducted to assess publication biases for mortality, combined GFO, GOS, and mRS. A statistical power analysis was conducted to account for varying sample sizes at the various time points for each of the outcome measures.
Results
A PubMed search using the terms ''IVH'' and ''IVH and ICH'' yielded 532 results. Subsequently, case studies, non-primary IVH studies, and studies not listing outcomes were excluded yielding 185 studies for further analysis. Publications without a control group, studying traumatic hemorrhages, including non-hypertensive hemorrhages, and where treatment of IVH with IVF was not the primary treatment were excluded, leaving 38 studies. Finally, studies including patients with vascular abnormalities such as aneurysms or AVMs were excluded. An exception was made for three publications listing individual patient data, which allowed patients with vascular abnormalities to be removed from our analysis. [15] [16] [17] This left a final cohort of 17 publications ( Figure 1 and Table 1) .
A search of China databases CNKI, VIP, and Wanfang yielded 1092 results. Exclusion of publications without treatment of IVH as the primary focus yielded 602 results. Furthermore, 22 studies included hypertensive hemorrhages and EVD with IVF as the main treatment variable. Finally, none of the China publications met our inclusion criteria of hypertensive IVH without vascular abnormalities. (Supplemental Figure B) .
Mortality rates were lower in the treatment group at 30 days (RR, 0.50; 95% CI, 0.35-0.70; P < 0.001;180 days (RR, 0.60; 95% CI, 0.44-0.82; P ¼ 0.001), 365 days (RR, 0.72; 95% CI, 0.33-1.55; P ¼ 0.40), and overall (RR, 0.56; 95% CI, 0.45-0.70; P < 0.001; Figure 2 ). For studies that evaluated mRS, GFO was more common in the treatment group at 30 days (RR, 0.96; 95% CI, 0.81-1.13; P ¼ 0.60), 90 days (RR, 0.57; 95% CI, 0.39-0.82; P < 0.01), 180 days (RR, 0.94; 95% CI, 0.80-1.11; P ¼ 0.48), 365 days (RR, 0.92; 95% CI, 0.55-1.55; P ¼ 0.76), and overall time points (RR, 0.89; 95% CI, 0.79-1.00; P ¼ 0.05). A significant difference only occurred at 90 days ( Figure 3 ).
For studies that evaluated GOS, more GFO were observed in the treatment group at 30 days (RR, 0.86; 95% CI, 0.63-1.16; P ¼ 0.31), 90 days (RR, 0.43; 95% CI, 0.18-1.00; P < 0.05), 180 days (RR, 0.66; 95% CI, 0.52-0.85 P ¼ 0.001), and overall (RR, 0.67; 95% CI, 0.55-0.83; P < 0.001; Figure 4 ). Pooling mRS and GOS data according to the GFO definitions (mRS 0-3 and GOS 3-5), the treatment group had more GFO at 30 days (RR, 0.94; 95% CI, 0.81-1.08; P ¼ 0.38), 90 days (RR, 0.43; 95% CI, 0.19-0.97; P ¼ 0.04), 180 days (RR, 0.81; 95% CI, 0.54-1.21; P ¼ 0.31), 365 days (RR, 0.92; 95% CI, 0.55-1.55; P ¼ 0.76), and overall (RR, 0.85; 95% CI, 0.73-0.98; P ¼ 0.02; Figure 5 ).
There was low heterogeneity between studies for all timepoints for mortality, and for 30 day and overall mRS ( Figures 2 and 3 ). For the GOS plot, there was low heterogeneity at 30 and 180 days, moderate heterogeneity with all time points combined, and substantial heterogeneity at 90 days ( Figure 4) . When assessing GFO, there was low heterogeneity at 30 days, substantial heterogeneity at 90 and 180 days, and moderate heterogeneity overall ( Figure 5 ). 23 Heterogeneity was not calculated for single study time points.
Sensitivity analyses revealed RR estimates for mortality comparing treatment and control ranging from 0.46 to 0.54 at 30 days, 0.45 to 0.62 at 180 days, and 0.13 to 0.88 at 365 days (Supplemental table A). mRS only RR estimates comparing treatment and control International Journal of Stroke, 13(1) International Journal of Stroke, 13(1) International Journal of Stroke, 13(1) Randomized control trials were assessed for quality using the Jadad scale where a maximum of two points was awarded for randomization, two points for blinding, and one point for an accounting of all patients. The Newcastle-Ottawa Quality Assessment Scale was used for nonrandomized control trials where a maximum of four stars (****) was awarded for selection, two stars (**) for comparability, and three stars (***) for outcome. 
Discussion
The goal of this meta-analysis was to assess the effect of IVF treatment of hypertensive IVH compared to EVD alone or EVD plus intraventricular saline in a larger patient cohort at various time points. Results demonstrate an apparent effect of IVF treatment on mortality and possible effect on GFO compared to control.
We attempted to remove outcome-related confounding variables by removing publications or individual patient data with vascular abnormalities. Previous meta-analyses have included these patients. [15] [16] [17] There are many confounding factors that may be important that cannot be accounted for due to data constraints however, results from this meta-analysis are consistent with previous meta-analyses. 10, 12 It was not possible to distinguish between primary and secondary IVH or to control for IVH volume evacuated due to limited individual patient data. Furthermore, only two publications reported the number of patients reaching the third and fourth ventricle clearance end point. Data from the CLEAR III trial suggest that IVH volume evacuated may affect mortality and functional outcome however, future studies are needed to assess this. 7 When appropriate data become available, a meta-analysis should be completed to further assess the importance of these factors. This paper is limited by probable heterogeneity in IVH removal, EVD placement strategies, and medical comorbidities across studies. The assumption is that the response to IVF therapy is uniform; although this may not be accurate, the beneficial response of IVH to IVF treatment compared to EVD alone has not been rejected by this metaanalysis.
Mortality
Overall mortality rates were lower in hypertensive IVH patients treated with IVF at all time points. 
11,30
One likely explanation is that Hallevi et al. did not use IVH volume-matched controls to compare to the IVF group. 30 Similarly, Volbers et al. had drastically different IVH volume for the treatment group (26.9 AE 19.2 ml) and for the control group (9.2 AE 13.4 ml). Patients in the treatment group may have had a worse prognosis in comparison to the control group due to higher initial IVH volumes. 11 Overall, this meta-analysis demonstrates that patients survived more often if treated with IVF, a trend that was observed through day 365. These results demonstrate that treating patients with IVF likely provides a long-term survival benefit in patients with hypertensive IVH. 
Good functional outcome
Generally, functional outcome is measured using either the mRS or the GOS. Eight publications assessed functional outcome using mRS while six used GOS. Three of these publications measured both at the same time point, where mRS was used for the combined GFO analysis. This resulted in 11 unduplicated patient cohorts for the combined GFO analysis. For the few publications that did not present outcome data that could be dichotomized, supplementary data were obtained from the researchers. 8, 13, 29, 31 The data were analyzed and standardized GFO definitions were implemented. One publication, Torres et al., remained unchanged due to data access constraints that only allowed dichotomization as defined by the study-GFO as GOS 4-5. 28 However, omitting this study during sensitivity analyses did not significantly impact the results (Supplemental table D) .
Results of this meta-analysis show that combined GFO possibly favored the IVF group at all time points, although statistical significance was only reached at 90 days and overall (P ¼ 0.04; P ¼ 0.02). Figure 5 ). One possible explanation is that the study included control patients with a higher volume of IVH compared to the treatment group; 63% of control patients had a grade IV IVH (IVH fills length of both ventricles), while only 20% of the treatment cohort were grade IV IVH. This may have led to inflated GFOs in the treatment group since these patients were better off from disease onset. 25 This resulted in a sizeable 90-day RR CI (Supplemental table D). Another issue is that the threshold for a good GOS score is more lenient because it includes severely disabled patients yet mRS does not. These characteristics may explain some of the differences between mRS and GOS estimates of GFO.
When mRS scores alone are analyzed for GFO, there is only a statistically significant difference at 90 days where one study reported data (RR, 0.57; 95% CI, 0.39-0.82; P < 0.01; Figure 3 ). However, when GOS scores are analyzed for GFO, there is a significant difference favoring the IVF group at 90, 180, and overall (RR, 0.43 CI, 0.18-1.00, P < 0.05; RR, 0.66 CI, 0.52-0.85; P ¼ 0.001; RR 0.67, CI 0.55-0.83, Figure 4 . Forest plot of GOS by timepoint reported as a relative risk. GFO was defined as a GOS score of 3 to 5. GOS: Glasgow outcome scale; GFO: good functional outcome. P < 0.001; Figure 4 ). This may be due to the difference in scale sensitivity, given the specified mRS and GOS GFO definitions.
For mRS, a score of 3 is defined as moderate disability-requiring some help, but able to walk without assistance. 32 A good GOS score is defined as 3-5; a score of 3 defined as severe disability (conscious but disabled)-''patients who are dependent for daily support by reason of mental or physical disability, usually a combination of both.'' 33 A GOS of 3-5 may overestimate the number of patients with GFO, while a mRS of 0-3 may yield a more conservative estimate. A subanalysis of CLEAR III data revealed that 89.3% of GFO patients (in the GOS 3-5 group) had a GOS score of 3 at day 30. 7 A GOS of 3 was defined as a good outcome in this meta-analysis, but it varies in clinical meaning with the upper limit of GFO for mRS, which is 3. This leads to statistically significant GOS GFO measurements for the treatment groups that were not always seen when using the mRS scale.
Furthermore, a GOS of 3 may be considered a good outcome at 30 days but not at 365 days when more recovery is expected to have occurred. This is an important consideration when evaluating patients' recovery over time and interpreting functional outcome data.
Additionally, it is important to consider differences in IVH removal across studies. The dosing end point for 10 out of 17 studies was clearance of the third and fourth ventricles; however, only two studies reported how many of their patients reached end point. Huttner et al. reported that 45.5% of patients in the IVF group reached the ventricular opening end point, whereas in Hanley et al., 32 .9% of patients in the treatment group and 9.6% of patients in the saline group achieved a more robust endpoint: > 80% removal. 7, 9 Collecting data on IVH clearance may be of great Figure 5 . Forest plot of combined GFO (mRS and GOS) by timepoint reported as a relative risk. GFO was defined as a mRS 0 to 3 or a GOS of 3 to 5. GFO: good functional outcome; mRS: modified Rankin Scale; GOS: Glasgow outcome scale. value since differences in IVH clearance across studies may account for some of the variability in GFOs.
This meta-analysis is unique in that patients with vascular abnormalities were excluded in order to assess a homogeneous patient cohort. Additionally, a larger patient cohort was accessed with the incorporation of the CLEAR III trial. 7 Furthermore, defining specific thresholds for mRS and GOS served to produce GFO data that could be combined across studies when possible. mRS, GOS, and mortality data were also evaluated by time point in order to observe the effect of IVF treatment on progression of recovery an approach that has not been done in other meta-analyses.
Limitations
Some limitations of this meta-analysis include the lack of multiple large randomized controlled trials that assess IVF therapy for IVH. This limits the ability to assess established severity factors in both treatment groups such as (IVH size, ICH size, presenting GCS, and age). Additionally, some publications reported limited functional outcome data. 6, 7 This meta-analysis did not distinguish between different fibrinolytics such as tissue plasminogen activator (tPA) or Urokinase, dosing regimens, or primary and secondary IVH.
Conclusion
Treatment of hypertensive IVH with IVF therapy reduces mortality compared to control groups as early as 30 days, a trend that continues through 365 days. Different effect sizes are generated when different functional outcome tools, such as mRS and GOS, are used. Fibrinolytic treatment may offer IVH patients a targeted therapy that appears to produce meaningful mortality and possible functional outcome benefits.
